Drug Safety

, Volume 24, Issue 14, pp 1039–1053 | Cite as

Comparative Tolerability of First-Generation Selective Estrogen Receptor Modulators in Breast Cancer Treatment and Prevention

Review Article

Abstract

In general, the selective estrogen receptor modulators (SERMs) currently indicated for the treatment and prevention of breast cancer, i.e. tamoxifen and toremifene, are fairly well tolerated. However, tamoxifen has been shown to induce hepatocellular carcinomas in rats, but not in humans, and can increase the risk of endometrial cancer in humans by two to three times. Other potentially serious adverse effects which have been associated with tamoxifen and toremifene therapy include vasomotor symptoms, an increased risk of venous thromboembolic events, and an increased incidence of cataracts and ocular toxicity, fatty liver, and nonmalignant hepatic and uterine changes. In addition, long term tamoxifen use almost always results in resistance to the drug and, indeed, has actually been shown to promote tumour proliferation in human breast cancer cells. Both tamoxifen and toremifene display drug interactions with a variety of drug classes.

The adverse events associated with these compounds have raised significant concerns regarding their widespread use for the treatment and prevention of breast cancer. In addition, because of the weakness and scarcity of the data on toremifene, any conclusions about its tolerability remain tentative until outcomes of ongoing clinical trials in the adjuvant setting are known. A third SERM, raloxifene, is the focus of several large randomised trials examining its efficacy in the prevention of breast cancer. At present, each potential adverse event needs to be weighed against potential benefits in the decision to undergo SERM treatment. An array of therapies is currently available for patients with breast cancer and women at increased risk of disease; the risk-to-benefit ratio for each agent should be carefully examined in determining the most advantageous regimen.

References

  1. 1.
    American Cancer Society. Cancer facts & figures: 1998. Atlanta (GA): American Cancer Society, 1998Google Scholar
  2. 2.
    Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; II: 104–7CrossRefGoogle Scholar
  3. 3.
    Toft D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci U S A 1966; 55(6): 1574–81PubMedCrossRefGoogle Scholar
  4. 4.
    Manni A. Hormonal approaches to the chemoprevention of endocrine-dependent tumors. Endocr Relat Cancer 1999; 6(4): 483–5PubMedCrossRefGoogle Scholar
  5. 5.
    Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem Suppl 1995; 22: 51–7PubMedCrossRefGoogle Scholar
  6. 6.
    Baker VL, Jaffe RB. Clinical uses of antiestrogens. Obstet Gynecol Surv 1996; 51(1): 45–59PubMedCrossRefGoogle Scholar
  7. 7.
    Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drugs Aging 1999; 14(5): 323–6PubMedCrossRefGoogle Scholar
  8. 8.
    Sato M, McClintock C, Kim J, et al. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 1994; 9(5): 715–24PubMedCrossRefGoogle Scholar
  9. 9.
    Paech K, Webb P, Kuiper GGJM, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997 Sep 5; 277(5331): 1508–10PubMedCrossRefGoogle Scholar
  10. 10.
    Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997 Oct 16; 389: 753–8PubMedCrossRefGoogle Scholar
  11. 11.
    Jordan VC. Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene. Recent Results Cancer Res 1998; 152: 265–76PubMedCrossRefGoogle Scholar
  12. 12.
    MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50(2): 151–96PubMedGoogle Scholar
  13. 13.
    Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000; 295 (2): 431–7Google Scholar
  14. 14.
    Mitlak BH, Cohen FJ. Selective estrogen modulators: a look ahead. Drugs 1999; 57(5): 653–3PubMedCrossRefGoogle Scholar
  15. 15.
    Joensuu H, Holli K, Oksanen H, et al. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000; 63(3): 225–34PubMedCrossRefGoogle Scholar
  16. 16.
    Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast Cancer Prevention Trial. J Natl Cancer Inst 2001; 93(1): 16–21PubMedCrossRefGoogle Scholar
  17. 17.
    Capony F, Rochefort H. High-affinity binding of the antiestrogen [3H]tamoxifen to the 8S estradiol receptor. Mol Cell Endocrinol 1978; 11(2): 181–98PubMedCrossRefGoogle Scholar
  18. 18.
    Friedl A, Jordan VC. What do we know and what don’twe know about tamoxifen in the human uterus. Breast Cancer Res Treat 1994; 31(1): 27–39PubMedCrossRefGoogle Scholar
  19. 19.
    Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13(2): 513–29PubMedGoogle Scholar
  20. 20.
    Early Breast Cancer Trialists’Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351 (9114): 1451–67Google Scholar
  21. 21.
    Hayes TG, Peterson LE, Weinberg AD. Current guidelines for the diagnosis and treatment of breast cancer. Dis Manage Health Outcomes 1998; 3(5): 239–50CrossRefGoogle Scholar
  22. 22.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90(18): 1371–88PubMedCrossRefGoogle Scholar
  23. 23.
    US Food and Drug Administration. Product approvals for cancer indications, June 2000 through June 1996 [online]. Available from URL: http://www.fda.gov/oashi/cancer/cdrug.html [Accessed 2001 Jan 15]
  24. 24.
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352(9122): 98–101PubMedCrossRefGoogle Scholar
  25. 25.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Lancet 1998; 352(9122): 93–7PubMedCrossRefGoogle Scholar
  26. 26.
    Kallio S, Kangas L, Blanco G, et al. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 1986; 17(2): 103–8PubMedCrossRefGoogle Scholar
  27. 27.
    Simberg NH, Murai JT, Siiteri PK. In vitro and in vivo binding of toremifene and its metabolites in rat uterus. J Steroid Biochem 1990; 36(3): 197–202PubMedCrossRefGoogle Scholar
  28. 28.
    Tomás E, Kauppila A, Blanco G, et al. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995; 59(2): 261–6PubMedCrossRefGoogle Scholar
  29. 29.
    Wiseman LR, Goa KL. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs 1997; 54(1): 141–60PubMedCrossRefGoogle Scholar
  30. 30.
    Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995 Oct; 13(10): 2556–66PubMedGoogle Scholar
  31. 31.
    Gershanovich M, Garin A, Baltina D, et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 1997; 45(3): 251–62PubMedCrossRefGoogle Scholar
  32. 32.
    Pyrhönen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the ‘nordic’ phase III study. Br J Cancer 1997; 76(2): 270–7PubMedCrossRefGoogle Scholar
  33. 33.
    Pyrhönen S, Ellmén J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56(2): 133–43PubMedCrossRefGoogle Scholar
  34. 34.
    Holli K. Adjuvant trials of toremifene vs tamoxifen: the European experience. Oncology (Huntingt) 1998; 12(3 Suppl. 5): 23–7Google Scholar
  35. 35.
    Holli K, Valavaara R, Blanco G, et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J Clin Oncol 2000; 18(20): 3487–94PubMedGoogle Scholar
  36. 36.
    Balfour JA, Goa KL. Raloxifene. Drugs Aging 1998; 12(4): 335–41PubMedCrossRefGoogle Scholar
  37. 37.
    Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm 2000; 57(18): 1669–78PubMedGoogle Scholar
  38. 38.
    Glasebrook AL, Philllips DL, Sluka JP. Multiple binding sites for the anti-estrogen raloxifene (LY156758) [abstract]. J Bone Miner Res 1993; 8Suppl. 1: S268Google Scholar
  39. 39.
    Grese TA, Cho S, Finley DR, et al. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 1997; 40(2): 146–67PubMedCrossRefGoogle Scholar
  40. 40.
    Cummings SR, Eckert S, Krueger KA, et al. The effects of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999; 281(23): 2189–97PubMedCrossRefGoogle Scholar
  41. 41.
    Vastag B. Breast cancer prevention study aims to overcome drug bias [news]. JAMA 2001; 285(4): 399–400PubMedCrossRefGoogle Scholar
  42. 42.
    Barrett-Connor E, Wenger NK, Grady D, et al. Coronary heart disease in women, randomized clinical trials, HERS and RUTH [editorial]. Maturitas 1998; 31(1): 1–7PubMedCrossRefGoogle Scholar
  43. 43.
    Eli Lilly and Company. Lilly’s raloxifene use for the heart (RUTH) trial expanded to include invasive breast cancer prevention as a primary objective [online]. Available from URL: http://newsroom.lilly.com/news/printstory.cfm?id=723 [Accessed 2001 Jan 15]
  44. 44.
    Lønning PE, Lien EA, Lundgren S, et al. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992; 22(5): 327–58PubMedCrossRefGoogle Scholar
  45. 45.
    Buzdar AU, Kau S, Hortobagyi GN, et al. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1994; 33(4): 313–6PubMedCrossRefGoogle Scholar
  46. 46.
    Rauschning W, Pritchard KI. Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat 1994; 31: 83–94PubMedCrossRefGoogle Scholar
  47. 47.
    Pfizer droloxifene breast cancer treatment NDA will not be submitted. FDC Reports Pink Sheet 1998 Jan 26; 60 (4): T&G-4Google Scholar
  48. 48.
    Hirsimäki P, Hirsimäki Y, Nieminen L, et al. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol 1993; 67(1): 49–54PubMedCrossRefGoogle Scholar
  49. 49.
    Kärki A, Mäntylä E, Hirsimäki Y, et al. Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis. Arch Toxicol 2000; 74(4-5): 249–56PubMedCrossRefGoogle Scholar
  50. 50.
    Williams GM, Iatropoulos MJ, Djordjevic MV, et al. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14(2): 315–7PubMedCrossRefGoogle Scholar
  51. 51.
    Wilking N, Isaksson E, von Schoultz E. Tamoxifen and secondary tumours: an update. Drug Saf 1997; 16(2): 104–7PubMedCrossRefGoogle Scholar
  52. 52.
    Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994; 30A(11): 1714–21PubMedCrossRefGoogle Scholar
  53. 53.
    Mäenpää JU, Ala-Fossi S-L. Toremifene in postmenopausal breast cancer: efficacy, safety and cost. Drugs Aging 1997; 11(4): 261–70PubMedCrossRefGoogle Scholar
  54. 54.
    Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; i(8630): 117–20CrossRefGoogle Scholar
  55. 55.
    Assikis VJ, Neven P, Jordan VC, et al. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996; 32A(9): 1464–76PubMedCrossRefGoogle Scholar
  56. 56.
    Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ALERT Group: assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000; 356(9233): 881–7PubMedCrossRefGoogle Scholar
  57. 57.
    Mäenpää J, Holli K, Pasanen T. Toremifene: where do we stand? Eur J Cancer 2000; 36Suppl. 4: 61–2CrossRefGoogle Scholar
  58. 58.
    Osborne CK, Coronado EB, Robinson JP. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987; 23(8): 1189–96PubMedCrossRefGoogle Scholar
  59. 59.
    Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988; 48(18): 5183–7PubMedGoogle Scholar
  60. 60.
    Murata Y, Ogawa Y, Saibara T, et al. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 2000; 7(6): 1299–304PubMedGoogle Scholar
  61. 61.
    Hamada N, Ogawa Y, Saibara T, et al. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 2000; 17(6): 1119–23PubMedGoogle Scholar
  62. 62.
    Ismail SM. Gynaecological effects of tamoxifen. J Clin Pathol 1999; 52(2): 83–8PubMedCrossRefGoogle Scholar
  63. 63.
    Love CD, Muir BB, Scrimgeour JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17(7): 2050–4PubMedGoogle Scholar
  64. 64.
    Mourits MJE, de Vries EGE, Willemse PHB, et al. Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer 1999; 79(11-12): 1761–4PubMedCrossRefGoogle Scholar
  65. 65.
    Yao K, Jordan VC. Questions about tamoxifen and the future use of antiestrogens. Oncologist 1998; 3(2): 104–10PubMedGoogle Scholar
  66. 66.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93(9): 684–90PubMedCrossRefGoogle Scholar
  67. 67.
    Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93(6): 456–62PubMedCrossRefGoogle Scholar
  68. 68.
    Baum M. Tamoxifen: the treatment of choice. Why look for alternatives? Br J Cancer 1998; 78Suppl. 4: 1–4PubMedCrossRefGoogle Scholar
  69. 69.
    Carthew P, Martin EA, White IN, et al. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res 1995; 55(3): 544–7PubMedGoogle Scholar
  70. 70.
    Mani C, Kupfer D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 1991; 51(22): 6052–8PubMedGoogle Scholar
  71. 71.
    Mani C, Pearce R, Parkinson A, et al. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 1994; 15(12): 2715–20PubMedCrossRefGoogle Scholar
  72. 72.
    Han X, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992 Mar 1; 52(5): 1360–3PubMedGoogle Scholar
  73. 73.
    Pathak DN, Bodell WJ. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 1994; 15(3): 529–32PubMedCrossRefGoogle Scholar
  74. 74.
    Martin EA, Rich KJ, White IN, et al. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995; 16(7): 1651–4PubMedCrossRefGoogle Scholar
  75. 75.
    Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86(7): 527–37PubMedCrossRefGoogle Scholar
  76. 76.
    Mühlemann K, Cook LS, Weiss NS. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res Treat 1994; 30(2): 201–4PubMedCrossRefGoogle Scholar
  77. 77.
    Catherino WH, Jordan VC. A risk-benefit assessment of tamoxifen therapy. Drug Saf 1993; 8(5): 381–97PubMedCrossRefGoogle Scholar
  78. 78.
    Plowman PN. Tamoxifen as adjuvant therapy in breast cancer: current status. Drugs 1993; 46(5): 819–33PubMedCrossRefGoogle Scholar
  79. 79.
    Hemminki K, Widlak P, Hou S-M. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 1995; 16(7): 1661–4PubMedCrossRefGoogle Scholar
  80. 80.
    Davies AM, Martin EA, Jones RM, et al. Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis 1995; 16(3): 539–45PubMedCrossRefGoogle Scholar
  81. 81.
    Styles JA, Davies A, Davies R, et al. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). Carcinogenesis 1997; 18(2): 303–13PubMedCrossRefGoogle Scholar
  82. 82.
    Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985; 69(2): 237–8PubMedGoogle Scholar
  83. 83.
    Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 1995; 59(2): 186–90PubMedCrossRefGoogle Scholar
  84. 84.
    International Agency for Research on Cancer. Some pharmaceutical drugs. Lyon, France: International Agency for Research on Cancer, 1996Google Scholar
  85. 85.
    Cohen CJ. Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Semin Oncol 1997; 24(1 Suppl. 1): S55–64Google Scholar
  86. 86.
    Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 1997; 24(1 Suppl. 1): S140–50Google Scholar
  87. 87.
    Wogan GN. Review of the toxicology of tamoxifen. Semin Oncol 1997; 24(1 Suppl. 1): S87–97Google Scholar
  88. 88.
    Stewart HJ, Knight GM. Tamoxifen and the uterus and endometrium [letter]. Lancet 1989; 1(8634): 375–6PubMedGoogle Scholar
  89. 89.
    Ribeiro G, Swindell R. The Christie hospital adjuvant tamoxifen trial: status at 10 years. Br J Cancer 1988; 57(6): 601–3PubMedCrossRefGoogle Scholar
  90. 90.
    Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83(14): 1013–7PubMedCrossRefGoogle Scholar
  91. 91.
    van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343(8895): 448–52PubMedCrossRefGoogle Scholar
  92. 92.
    Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984; 44(9): 4006–10PubMedGoogle Scholar
  93. 93.
    Gottardis MM, Ricchio ME, Satyaswaroop PG, et al. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 1990; 50(11): 3189–92PubMedGoogle Scholar
  94. 94.
    Mäenpää J, Ellmén J, Pasanen T, et al. Re: effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth [letter]. J Natl Cancer Inst 1999; 91(11): 972–3PubMedCrossRefGoogle Scholar
  95. 95.
    Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87(9): 645–51PubMedCrossRefGoogle Scholar
  96. 96.
    Fentiman IS. Tamoxifen and mastalgia. An emerging indication. Drugs 1986; 32(6): 477–80PubMedCrossRefGoogle Scholar
  97. 97.
    Love RR, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151: 1842–7PubMedCrossRefGoogle Scholar
  98. 98.
    Robinson E, Kimmick GG, Muss HB. Tamoxifen in postmenopausal women: a safety perspective. Drugs Aging 1996; 8(5): 329–7PubMedCrossRefGoogle Scholar
  99. 99.
    Gundersen S. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer: a phase II study. J Steroid Biochem 1990; 36(3): 233–4PubMedCrossRefGoogle Scholar
  100. 100.
    Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9(2): 286–94PubMedGoogle Scholar
  101. 101.
    Nayfield SG, Gorin MB. Tamoxifen-associated eye disease: a review. J Clin Oncol 1996; 14(3): 1018–26PubMedGoogle Scholar
  102. 102.
    Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992 Jun 15; 69(12): 2961–4PubMedCrossRefGoogle Scholar
  103. 103.
    Therssen R, Jansen E, Leys A, et al. Screening for tamoxifen ocular toxicity: a prospective study. Eur J Ophthalmol 1995; 5(4): 230–4PubMedGoogle Scholar
  104. 104.
    Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000; 60(2): 167–72PubMedCrossRefGoogle Scholar
  105. 105.
    Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998; 125(4): 493–501PubMedCrossRefGoogle Scholar
  106. 106.
    Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis [letter]. Ann Intern Med 1995 Aug 1; 123(3): 236PubMedGoogle Scholar
  107. 107.
    Ogawa Y, Murata Y, Nishioka A, et al. Tamoxifen-induced fatty liver in patients with breast cancer [letter]. Lancet 1998; 351(9104): 725PubMedCrossRefGoogle Scholar
  108. 108.
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 1989; 320(8): 479–84PubMedCrossRefGoogle Scholar
  109. 109.
    Neven P, De Muylder X, Van Belle Y, et al. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynaecol Reprod Biol 1990; 35: 235–8CrossRefGoogle Scholar
  110. 110.
    Mourits MJ, Van der Zee AG, Willemse PH, et al. The ovary: cysts, screening, and tamoxifen [letter]. Lancet 2000; 355(9220): 2078–9PubMedCrossRefGoogle Scholar
  111. 111.
    Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 2000; 22(1): 1–11PubMedCrossRefGoogle Scholar
  112. 112.
    Gerber B, Krause A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18(20): 3464–70PubMedGoogle Scholar
  113. 113.
    Mourits MJE, de Vries EGE, Willemse PHB, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97(5 Pt 2): 855–66PubMedCrossRefGoogle Scholar
  114. 114.
    Mourits MJ, Willemse PH, De Vries EG, et al. Tamoxifen and endometrial screening. J Clin Oncol 2000; 18(2): 446–8PubMedGoogle Scholar
  115. 115.
    Barakat RR. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer. J Clin Oncol 1999; 17(7): 1967–8PubMedGoogle Scholar
  116. 116.
    Barakat RR, Gilewski TA, Almadrones L, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 2000; 18(20): 3459–63PubMedGoogle Scholar
  117. 117.
    Runowicz CD. Gynecologic surveillance of women on tamoxifen: first do no harm. J Clin Oncol 2000; 18(20): 3457–8PubMedGoogle Scholar
  118. 118.
    Schering Corporation. Fareston® (toremifene citrate) [product information]. Kenilworth (NJ): Schering Corporation, 1997Google Scholar
  119. 119.
    AstraZeneca. Nolvadex® (tamoxifen citrate) [product information]. Wilmington (DE): AstraZeneca, 1999Google Scholar
  120. 120.
    Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. BMJ 1987; 295(6606): 1141PubMedCrossRefGoogle Scholar
  121. 121.
    Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ 1989; 298(6666): 93PubMedCrossRefGoogle Scholar
  122. 122.
    Pritchard KI, Paterson A, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996; 14(10): 2731–7PubMedGoogle Scholar
  123. 123.
    Corona G, Aita P, Sorio R, et al. Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. Anticancer Drugs 1999; 10(9): 815–9PubMedCrossRefGoogle Scholar
  124. 124.
    Nease Jr RF, Ross JM. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs. Am J Med 1995 Aug; 99: 180–9PubMedCrossRefGoogle Scholar
  125. 125.
    Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999; 6(1): 75–92PubMedCrossRefGoogle Scholar
  126. 126.
    Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19(10): 2596–606PubMedGoogle Scholar
  127. 127.
    Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomised phase III trial. Eur J Cancer 2000; 36Suppl. 4: S81–91Google Scholar
  128. 128.
    Novartis. FDA Advisory Committee unanimously recommends approval of Novartis drug, Femara (letrozole tablets), as first-line treatment for advanced breast cancer [online]. Available from URL: http://www.pharma.us.novartis.com/cgi-bin/pressreleases.pl?Todo=getStory&newsID=98 [Accessed 2001 Jan 12]
  129. 129.
    Santen RJ, Yue W, Naftolin F, et al. The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer 1999; 6(2): 235–43PubMedCrossRefGoogle Scholar
  130. 130.
    Spicer DV, Pike MC. Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr 1994; (16): 139–47PubMedGoogle Scholar
  131. 131.
    Nelson NJ. Hormonal manipulations may also reduce breast cancer risk [news]. J Natl Cancer Inst 1999; 91(11): 910–1PubMedCrossRefGoogle Scholar
  132. 132.
    Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors: a time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group [published erratum appears in JAMA 1995 Feb 1; 273 (5): 378]. JAMA 1994 Aug 17; 272(7): 540–5PubMedCrossRefGoogle Scholar
  133. 133.
    Jacobs HS. Hormone replacement therapy and breast cancer. Endocr Relat Cancer 2000; 7(1): 53–61PubMedCrossRefGoogle Scholar
  134. 134.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59Google Scholar
  135. 135.
    O’Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001; 93(10): 754–61PubMedCrossRefGoogle Scholar
  136. 136.
    Homesley HD, Shemano I, Gams RA, et al. Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 1993; 16(2): 117–22PubMedCrossRefGoogle Scholar
  137. 137.
    di Salle E, Zaccheo T, Ornati G. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 1990; 36(3): 203–6PubMedCrossRefGoogle Scholar
  138. 138.
    Plowman PN. Adjuvant therapy in breast cancer. Optimal use in the elderly. Drugs Aging 1996; 9(3): 185–90PubMedCrossRefGoogle Scholar
  139. 139.
    Smedira HJ. Practical issues in counseling healthy women about their breast cancer risk and use of tamoxifen citrate. Arch Intern Med 2000; 160(20): 3034–42PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2001

Authors and Affiliations

  1. 1.Department of Obstetrics/GynecologyUniversity of Texas at HoustonHoustonUSA

Personalised recommendations